» Authors » Philippe Clapuyt

Philippe Clapuyt

Explore the profile of Philippe Clapuyt including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 53
Citations 1075
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Seront E, Biard J, Van Damme A, Revencu N, Lengele B, Schmitz S, et al.
Nat Cardiovasc Res . 2024 Aug; 2(6):595-599. PMID: 39195878
Sirolimus, by targeting the mammalian target of rapamycin (mTOR) pathway, has demonstrated efficacy on lymphatic malformations (LMs) in adults and neonates. The current hypothesis is that the earlier the lesion...
2.
Boon L, Dekeuleneer V, Coulie J, Marot L, Bataille A, Hammer F, et al.
Nat Cardiovasc Res . 2024 Aug; 1(6):562-567. PMID: 39195866
Arteriovenous malformations (AVMs) are fast-flow lesions that may be destructive and are the most difficult-to-treat vascular anomalies. Embolization followed by surgical resection is commonly used; however, complete resection is rarely...
3.
Seront E, Froidure A, Revencu N, Dekeuleneer V, Clapuyt P, Dumitriu D, et al.
Orphanet J Rare Dis . 2024 May; 19(1):199. PMID: 38750525
Repurposing anticancer drugs to vascular malformations has significantly improved patient outcomes. Complex Lymphatic Anomalies (CLA) are part of the spectrum of lymphatic malformations (LMs) that share similar oncogenic mutations to...
4.
Seront E, Van Damme A, Legrand C, Bisdorff-Bresson A, Orcel P, Funck-Brentano T, et al.
JCI Insight . 2023 Nov; 8(21. PMID: 37937645
BACKGROUNDSlow-flow vascular malformations frequently harbor activating mutations in the PI3K/AKT/mTOR cascade. Phase II trials pinpointed sirolimus effectiveness as a drug therapy. Efficacy and safety of sirolimus thus need to be...
5.
Ramboux A, Poncelet A, Clapuyt P, Scheers I, Sokal E, Reding R, et al.
J Med Case Rep . 2023 Sep; 17(1):413. PMID: 37775787
Background: Deoxyguanosine kinase deficiency is mainly manifested by hepatic and neurological damage, hence it belongs to the hepatocerebral form of mitochondrial deoxyribonucleic acid depletion syndrome. The association between deoxyguanosine kinase...
6.
De Smedt F, Dessy F, Carestia L, Baldin P, Aboubakar Nana F, Clapuyt P, et al.
Oncol Lett . 2023 Jan; 25(2):54. PMID: 36644155
Oncogenic rearrangements in the anaplastic lymphoma kinase (ALK) gene account for 5% of non-small cell lung cancer (NSCLC) cases. ALK inhibitors have markedly improved the outcome of metastatic ALK-positive NSCLC...
7.
Hoornaert E, Clapuyt P, Dumitriu D, Niel O, Huybrechts S, Scheers I, et al.
Clin Case Rep . 2022 Jul; 10(7):e05938. PMID: 35846904
Involution of a rapidly involuting congenital hemangioma is an unknown cause of neonatal ascites. As involution phase is completed by 14 months after birth, conservative management with diuretics and drainage...
8.
Dumitriu D, Menten R, Clapuyt P
Pediatr Radiol . 2022 Feb; 52(7):1392-1403. PMID: 35171298
Ultrasound (US) is widely used in pediatric musculoskeletal pathology at all ages. Although the focus is often on soft tissues, joints and cartilage, the examiner might be confronted with changes...
9.
Brouillard P, Schlogel M, Homayun Sepehr N, Helaers R, Queisser A, Fastre E, et al.
Orphanet J Rare Dis . 2021 Jun; 16(1):267. PMID: 34112235
Background: Theragnostic management, treatment according to precise pathological molecular targets, requests to unravel patients' genotypes. We used targeted next-generation sequencing (NGS) or digital droplet polymerase chain reaction (ddPCR) to screen...
10.
Biard J, Payrat S, Clapuyt P, Barrea C, Benoit V, Baldin P, et al.
Eur J Med Genet . 2021 Mar; 64(4):104189. PMID: 33662639
Although the prognosis of CHARGE syndrome can be highly variable from mild until severe, final diagnosis is difficult to establish in utero. The aim of our study is to compare...